Gael Clergeaud Veiga

Produktionstorvet, 423, 210
2800 Kgs. Lyngby
Denmark

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Gael Clergeaud Veiga is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

15 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots or

6 Journal article
4 Poster
2 Conference abstract in journal
1 Patent

Cell-penetrating conjugate systems
Srivastava, S., Veiga, G. & Boisen, A., 15 Oct 2020, IPC No. A61K 47/ 18 A I, Patent No. WO2020207974, 6 Apr 2020, Priority date 10 Apr 2019, Priority No. EP20190168314
Research output: Patent

Open Access
File
18 Downloads (Pure)
Deep TLR Primed (TM) T cells induce potent antitumor activity without systemic toxicity
Westcott, N., Boesch, A., Rybakin, V., Hwang, J. Y., Jørgensen, K. R., Lassen, R., Kræmer, M. K., Bak, M., Veiga, G., Bruun, J., Tassa, C., Rodts, H., Sequeira, M., Sauer, K. & Andresen, T. L., 2020, In : Cancer Immunology Research . 8, 3 , p. 118-118 1 p., B66.
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Hemoglobin-Based Oxygen Carriers Incorporating Nanozymes for the Depletion of Reactive Oxygen Species
Jansman, M. M. T., Liu, X., Kempen, P., Clergeaud, G., Andresen, T. L., Thulstrup, P. W. & Hosta-Rigau, L., 2020, In : ACS Applied Materials and Interfaces. 12, 45, p. 50275–50286
Research output: Contribution to journal › Journal article › Research › peer-review
Deep TLR Primed^TM T cells induce potent anti-tumor activity without systemic toxicity
Westcott, N., Boesch, A., Rybakin, V., Hwang, J. Y., Jørgensen, K., Lassen, R., Kræmer, M., Bak, M., Veiga, G., Bruun, J., Tassa, C., Rodts, H., Sequeira, M., Sauer, K. & Andresen, T. L., 2019.
Research output: Contribution to conference › Poster › Research › peer-review

Open Access
File

123 Downloads (Pure)
Delivery of TLR7 agonists by Deep-Primed (TM) T cells induces immune activation and improves anti-tumor activity in mice while circumventing systemic toxicity
Boesch, A., Rybakin, V., Westcott, N., Hwang, J. Y., Jørgensen, K. R., Lassen, R., Kræmer, M. K., Bak, M., Veiga, G., Bruun, J., Tassa, C., Rodts, H., Sequeira, M., Leary, G., Caruso, S., Hewes, B., Fitzgerald, J., Sauer, K. & Andresen, T. L., 2019, In : Journal for ImmunoTherapy of Cancer. 7, Suppl. 1, P671.
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

2 Active

Optimizing solid cancer treatment with local immono-gel injection with immunostimulatory drugs
Xin, L., Andresen, T. L., Petersen, L. R. & Clergeaud Veiga, G.
01/04/2019 → 31/03/2022
Project: PhD
Developing a novel method using nanoparticles to expand cancer-specific T-cells in vitro
Weller, S., Andresen, T. L., Petersen, L. R. & Clergeaud Veiga, G.
15/11/2018 → 14/11/2021
Project: PhD

1 Conference presentations

Novel liposomal vaccination platform for the co-delivery of cancer neo-epitopes and TLR7-agonist
Gael Clergeaud Veiga (Guest lecturer), Ditte Elisabeth Jæhger (Guest lecturer), Mie Linder Hübbe (Guest lecturer), Martin Kisha Kræmer (Guest lecturer), Anna Colliander (Guest lecturer), Martin Bak (Guest lecturer) & Thomas Lars Andresen (Guest lecturer)
15 Sep 2019 → 18 Sep 2019
Activity: Talks and presentations › Conference presentations